家族性阿尔茨海默氏症致病突变对粉样蛋白前体蛋白 (APP) 贩运,蛋白质分解转化和突触性活性的影响
Sandra Schilling1, Ajay Pradhan2, Amelie Heesch1
1Department of Human Biology and Human Genetics, University of Kaiserslautern, 67663, Kaiserslautern, Germany.
Acta neuropathologica communications
|May 31, 2023
概括
家族性阿尔茨海默氏症 (FAD) 突变在粉样前体蛋白 (APP) 的影响Aβ处理不同. 在分泌酶分裂部位的这些遗传变异揭示了FAD背后的独特的致病机制.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 与粉样蛋白前体蛋白 (APP) 和Aβ生成有关.
- 家庭性阿尔茨海默氏病 (FAD) 包括早期发病,具有多种APP突变的遗传病例.
- 对于FAD突变对APP处理的具体影响仍然不完全理解.
研究的目的:
- 为了比较APP中各种FAD突变的病原和生理差异.
- 研究FAD突变对APP处理和Aβ形状的影响.
- 阐明不同FAD突变背后的分子机制.
主要方法:
- 野生型 (WT) APP和FAD突变体在非神经细胞中的异质表达.
- 神经元的共同培养,以评估对前突触分化的影响.
- 使用免疫沉质谱法分析亚细胞局部化,内细胞化速率和蛋白质分解处理.
主要成果:
- 伊比利亚FAD突变独特地改变了协同生成功能.
- APP爱荷华突变体表现出α-分泌酶处理的减少和早期内分泌体中存在的增加.
- 免疫沉质谱学揭示了不同FAD突变的独特Aβ配置文件,包括弗兰德,北极和爱荷华突变的N-终端截断的Aβ (例如Aβ5).
结论:
- 在α-,β-和γ-分泌酶位点的家族AD突变在它们的致病机制中表现出显著的变化.
- APP突变对Aβ处理有差异性影响,导致Aβ形状和比率发生变化 (例如,Aβ40/Aβ42).
- 了解这些突变特异性机制对于破译FAD病原性至关重要.
相关概念视频
Alzheimer's Disease: Overview
539
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
539
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K


